Generative Biology

Generative biology refers to AI systems that design and predict biological molecules, genetic sequences, and protein structures to accelerate drug discovery and synthetic biology applications. Enterprises deploying these tools face novel compliance challenges around biosafety, intellectual property ownership of AI-generated sequences, and regulatory approval of compounds designed by machine learning models. Governance frameworks must address data provenance for training datasets, dual-use risks in pathogen research, and validation requirements that ensure AI-designed biologics meet pharmaceutical standards before human trials.

1 item

ResearchGlobal2026-08-15

AI-Designed Viruses Expose a Dual-Use Gap in Enterprise Governance Programs

Stanford researchers used the Evo 2 genomic language model to generate 16 functional bacteriophage genomes from scratch, with findings published in Science on August 6, 2026. Biosecurity experts at the Johns Hopkins Center for Health Security warn that the same methods lower the technical barrier to designing harmful biological agents. The research has prompted explicit calls for societal oversight frameworks, raising compliance obligations for any enterprise deploying or procuring AI tools with biological design capabilities.

biosecurity dual-use AI AI safety generative biology CBRN Stanford University Johns Hopkins life sciences